Adient Expands Buyback and Adopts 4.95% Poison Pill
ADNT is trading near its 52-week low of $15.91 (6.3% above the low).
Summary
Adient raised its share repurchase authorization and adopted a tax benefits preservation plan with a 4.95% ownership trigger and an $83.50 rights exercise price. The plan is a defensive structure designed to protect the company's net operating loss carryforwards from an ownership change, and the 4.95% threshold is tight enough to deter activists. The buyback increase builds on the $400M authorization extended alongside this morning's FY26 results, which showed $222M of free cash flow and FY27 EBITDA guidance of $900M-$925M. The combination of a larger repurchase program and a poison pill is a notable governance shift for a company with a roughly $1.3B market cap. Watch the November 16 CFO transition to Peter Carlin for any change in capital allocation priorities.
At the time of this announcement, ADNT was trading at $16.92 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $15.91 to $27.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.